Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Outlook Therapeutics Provides a Corporate Update and Business Outlook

Globe Newswire - Tue Jan 25, 2022

ISELIN, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today provided a business outlook for 2022.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

Premarket: U.S. futures muted as investors seek clues on rate path

The close: S&P 500 and TSX extend winning streaks, despite Disney drag

investor newsletter

A change in market leadership may be imminent. Plus, an index-beating U.S. dividend portfolio strategy

Tensions rise in Silicon Valley over sales of startup stocks

inside the market

How pro money managers are balancing exposure to Canadian and U.S. stocks

The close: TSX up more than 300 points to three-week high as rate cut hopes renew

The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada

The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings